Mpox in Africa: one year continental response outcomes and way forward.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Muteba Michel K, Mercy Kyeng, Boum Yap, Dereje Nebiyu, Tegegne Merawi Aragaw, Kabwe Patrick Chanda, Twyman Anthony, Atrah Yao S, Gumede-Moeletsi Hieronyma Nelisiwe, Ibeneme Charles Ugochukwu, Cho Wazih Nji, Ambe Laura, Njeba Beryl, Masina John, Armachie Joseph, Diallo Mamadou Saliou Kalifa, Nsasiirwe Sheillah, Mutombo Polydor, Bunyoga Denis, Kakule Deogratias, Sanni Olaniyi F, Nakame Rose Mary, Mamadu Ibrahim, Gonese Elizabeth, Kuissi Viviane, Kusena Priscilla, Mobula Linda Meta, Fossouo Viviane N, Shehu Usman, Kebede Selamawit, Kenta Bibi, Virayie Aurore, Hornsey Emilio, Makisonbooth Cat, Del Rio-Vilas Victor J, Fischer Natalie, Worku Masresha, Bhatnagar Aarunima, Matthews Eve, Harisson Abbie, Fallah Mosoka Papa, Folefack Gervais, Gaye Abou B, Keita Mory, Hall Shanelle, Ramadan Otim, Braka Fiona, Gueye Abdou Salam, Ngongo Ngashi, Kaseya Jean
Аннотация
METHODS: Key performance indicators across eight IMST pillars (coordination, surveillance, laboratory, case management, infection prevention and control, risk communication and community engagement (RCCE), vaccination and research) were descriptively analysed using data from 28 African Union Member States from January 2024 to August 2025.
RESULTS: A total of 49 803 confirmed cases and 240 deaths (CFR 0.5%) were recorded across 28 countries. The response was supported with US$977 million as tracked by the IMST. Operational achievements included 87% surveillance completeness, 72% contact tracing completeness and improved average laboratory turnaround time from >5 days to 2 days. Laboratory testing capacity expanded from 2 to 27 sites in the DRC and from 1 to 56 decentralised sites in Burundi. RCCE activities reached 50 million people in 21 countries, with vaccine acceptance among high-risk groups rising from 44% to 87%. Operational research achievements included a responsive and functional research coordination mechanism, 24 (92%, 24/26) multi-country clinical and operational research studies implemented and 60% completion rate of the research data and material sharing framework for Africa. Only 938 000 doses (32%) of the 3.1 million vaccine doses delivered were administered.
CONCLUSION: The joint continental IMST is a new benchmark for response governance, successfully mobilising resources and scaling up diagnostics under unified co-leadership. On the other hand, the evaluation revealed persistent structural challenges in last-mile vaccine delivery, contact tracing (due to stigma/funding) and weak regional collaborative research including fragmented regional research priorities. Future focus must shift from emergency action to durable, sustained investment in national and sub-national health security architecture using a multisectoral whole of government approach.